Sun Pharmaceutical Industries has secured the necessary shareholder approval from Organon to proceed with its $11.75 billion acquisition of the US-based women's health company.
The vote clears a critical path for the Indian drugmaker to take Organon private, transforming it into a wholly owned subsidiary following the completion of the all-cash deal.
75 billion. With the shareholder nod secured, the transaction can now move toward final regulatory clearances and closing formalities.
The approval marks a decisive step forward for one of the year’s most significant cross-border mergers in the pharmaceutical sector.
Sun Pharma originally announced the definitive agreement in April, setting an enterprise valuation of $11.75 billion.
With the shareholder nod secured, the transaction can now move toward final regulatory clearances and closing formalities.
The acquisition underscores Sun Pharma’s aggressive strategy to expand its global footprint and product portfolio through large-scale inorganic growth.